Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.1%

1 terminated/withdrawn out of 48 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

10%

5 trials in Phase 3/4

Results Transparency

8%

1 of 13 completed trials have results

Key Signals

16 recruiting1 with results

Enrollment Performance

Analytics

N/A
19(43.2%)
Phase 1
10(22.7%)
Phase 2
10(22.7%)
Phase 3
4(9.1%)
Phase 4
1(2.3%)
44Total
N/A(19)
Phase 1(10)
Phase 2(10)
Phase 3(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials
NCT04730154Not ApplicableActive Not Recruiting

PI-targeted PNE+MI Compared to BIOMEDICAL Education in BCS

Role: collaborator

NCT05256238Not ApplicableCompleted

Effect of Exercise in Head and Neck Cancer Patients

Role: collaborator

NCT05872204Phase 2Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Role: collaborator

NCT07558083Phase 3Recruiting

FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients

Role: collaborator

NCT06365788Phase 2Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Role: collaborator

NCT05656976Not ApplicableActive Not Recruiting

Efficacy of Offering a Self-sampling Device by the GP to Reach Underscreened Women

Role: collaborator

NCT07146074Not ApplicableRecruiting

Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases

Role: collaborator

NCT03676478Not ApplicableTerminated

Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival

Role: collaborator

NCT07121374Phase 1Recruiting

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Role: collaborator

NCT06691425Not ApplicableRecruiting

Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

Role: collaborator

NCT06962579Not ApplicableRecruiting

The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy

Role: collaborator

NCT05277766Phase 1Recruiting

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Role: collaborator

NCT02649829Phase 1Completed

Autologous Dendritic Cell Vaccination in Mesothelioma

Role: collaborator

NCT04078269Phase 1Completed

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

Role: collaborator

NCT05964361Phase 1Active Not Recruiting

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

Role: collaborator

NCT03903835Phase 3Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Role: collaborator

NCT06782412Phase 2Recruiting

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Role: collaborator

NCT04257461Phase 3Active Not Recruiting

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Role: collaborator

NCT04724928Phase 2Recruiting

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Role: collaborator

NCT05255133Not ApplicableCompleted

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

Role: collaborator